CHARGE syndrome is linked to autosomal-dominant mutations in the CHD7 gene and results in a number of physiological and structural abnormalities, including heart defects, hearing and vision loss, and gastrointestinal (GI) problems. Of these challenges, GI problems have a profound impact throughout an individual's life, resulting in increased morbidity and mortality. A homolog of CHD7 has been identified in the zebrafish, the loss of which recapitulates many of the features of the human disease. Using a morpholino chd7 knockdown model complemented by a chd7 null mutant zebrafish line, we examined GI structure, innervation, and motility in larval zebrafish. Loss of chd7 resulted in physically smaller GI tracts with normal epithelial and muscular histology, but decreased and disorganized vagal projections, particularly in the foregut. chd7 morphant larvae had significantly less ability to empty their GI tract of gavaged fluorescent beads, and this condition was only minimally improved by the prokinetic agents, domperidone and erythromycin, in keeping with mixed responses to these agents in patients with CHARGE syndrome. The conserved genetics and transparency of the zebrafish have provided new insights into the consequences of chd7 gene dysfunction on the GI system and cranial nerve patterning. These findings highlight the opportunity of the zebrafish to serve as a preclinical model for studying compounds that may improve GI motility in individuals with CHARGE syndrome.
Introduction
CHARGE syndrome is a genetic disorder with a prevalence of~1 in 10 000-15 000 births [1, 2] . The original anomalies were denoted by the CHARGE acronym: Coloboma of the eye, Heart defects, Atresia choanae, Retardation of growth and development, Genitourinary problems, and Ear abnormalities [3] . In the last 15 years, the clinical definition of CHARGE syndrome has expanded to include cranial nerve (CN) dysfunction [4] , as well as vestibular and semicircular canal anomaly [5] . In a Canadian survey of individuals clinically diagnosed with CHARGE syndrome, 92% exhibited symptoms reflective of at least one CN impairment and 72% reported involvement of more than one CN [6] . CN dysfunction was determined to be the primary clinical feature of CHARGE syndrome that impacts feeding, reflected in a high prevalence of weak sucking/chewing, swallowing difficulty, gastroesophageal reflux, and aspiration. As a result,~90% of individuals with CHARGE syndrome require early nasogastric tube feeding [7] and additional interventions such as gastric/ jejunal tube insertion, Nissan fundoplication, and lifelong medications to help manage gastrointestinal (GI) reflux and constipation. Cranial nerve X (CNX), the vagus nerve, is the longest CN and extends throughout the thorax and abdomen, providing innervation to the oropharynx, heart, and GI tract. While lesions of vagal projections to the pharynx and larynx are hypothesized to contribute to the difficulties in swallowing seen in many individuals with CHARGE syndrome [6] , it is unclear whether projections innervating the rest of the GI tract are similarly impacted.
Chromodomain helicase DNA-binding protein 7 (CHD7) has been identified as the primary causative gene of CHARGE syndrome [8] ; up to 80% of affected individuals present with an autosomal-dominant loss-of-function mutation in this gene [9, 10] . CHD7 belongs to the CHD family of ATP-dependent chromatin remodeling enzymes which have well-established roles in the epigenetic regulation of the fate of various stem cell populations, including those of the nervous system. For example, CHD7 promotes differentiation and proliferation of adult mouse neural stem cells in the central nervous system by epigenetic regulation of the transcription factors Sox4 and Sox11 [11] . However, there remain questions surrounding the development of the parasympathetic vagal nerve and enteric innervations of the GI tract of individuals with CHARGE syndrome as they relate to CHD7 loss of function, and subsequent functional outcomes leading to disordered intestinal motility.
The zebrafish (Danio rerio) is an excellent vertebrate model for genetic diseases, as it shares a high degree of genetic and developmental similarity with humans. A zebrafish homolog of CHD7 has been identified which has 69% amino acid sequence identity to the human protein [12] . Zebrafish larvae develop externally and at early developmental stages are optically transparent, facilitating the visualization of internal organs including the GI tube. By 4 days postfertilization (dpf), the GI tract has developed functionally and structurally into an intestinal bulb, midgut, and hindgut, and demonstrates anterograde and retrograde peristaltic movements, consistent with mature motility patterns [13, 14] . chd7 knockdown using morpholinos recapitulates a CHARGE-like phenotype in zebrafish larvae, including smaller eyes and defects of the heart, otoliths, developing vertebrae, craniofacial cartilage, and segmental blood vessels [12, 15] . Interestingly, these chd7 morphant larvae also show deformities in the branchiomotor neurons of the hindbrain, as well as decreased projection of the trigeminal (CNV) and facial (VII) nerves [15] . Similar deficits in these two nerve projections are the most likely cause of poor chewing and the facial palsy experienced by individuals with CHARGE syndrome [6] . However, CNX innervation of the intestine has not been previously explored in CHARGE syndrome nor have the functional consequences that might result from loss of vagal tone, such as decreased intestinal motility.
We hypothesized that a chd7 loss-of-function model in zebrafish could be used to investigate the GI difficulties reported in individuals with CHARGE syndrome. Here, we show that projections of CNX, as well as neural crest derived enteric nerve cell bodies of the foregut, are underdeveloped in chd7 morphants and mutants at 5 dpf. Furthermore, intestinal motility is significantly impaired in this CHARGE model and not easily ameliorated with common prokinetic drugs, in keeping with the therapeutic challenge observed in patients with CHARGE syndrome. This study represents the first report of a potential link between loss of intestinal innervation by the vagus nerve and decreased intestinal function in CHARGE syndrome.
Results
Loss of chd7 results in zebrafish larvae with CHARGE-like features Previous studies have described the expression of chd7 during embryogenesis in the zebrafish and have demonstrated a reproducible gross morphological phenotype in embryos injected with chd7-specific morpholinos [12, 15] . We were able to reproduce this phenotype, which included pericardial edema, smaller eyes, and abnormal curvature of the spine, using both translationblocking and splice-blocking morpholinos as demonstrated by Balow et al. [12] . Control embryos injected with 0.5 mM control morpholino developed normally. Larvae heterozygous for a 2-base pair deletion of exon 2 of chd7 generated using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology have similar developmental outcomes as the chd7 morphants along with pronounced cardiac defects at 3 dpf [16] (Fig. 1) . By employing a novel in vivo fluorescence reporter assay that we developed for the identification of deleterious mutations in zebrafish larvae, we determined that this 2-base pair deletion causes a lossof-function frameshift mutation in the chd7 gene [16] . The most common defect observed was an enlarged heart (cardiomegaly) with the atrium often being more enlarged than the ventricle. Situs inversus, where the chambers of the heart are located on opposite sides of the medial line of the body, was also observed.
chd7 morphant zebrafish larvae have smaller gastrointestinal tracts with intact intestinal epithelium
Both quantitative and qualitative characteristics of the size and morphology of the GI tract in chd7 and control morphant zebrafish (T€ ubingen) were evaluated. Using IMAGEJ software to measure the sagittal area of the GI tract from fluorescent images of these larvae (Figs 2A, C), we observed that the GI tract of the chd7 morphant fish was significantly reduced in size compared to those of control fish ( Fig. 2E ; P < 0.0001). Transverse sections were subsequently taken through the GI tract of chd7 morphant, mutant and control larvae, paraffinembedded, and stained with hematoxylin and eosin (H&E). The histology of the intestine of cdh7 morphants and mutants was comparable to wild-type T€ ubingen controls (Fig. 3) . Sections from control-injected morphants were also stained and showed similar phenotypes (data not shown). The intestinal epithelium appeared to be of similar thickness and composition among all groups, including the presence of an intact epithelial brush border of the intestinal bulb (Fig. 3A ,C,E) and the numbers of secretory goblet cells in the midgut (Fig. 3B,D,F) . There was also no obvious evidence of loss or reduction of intestinal muscularis in either the chd7 morphant or mutant larvae compared to controls (Fig. 3A,C,E) . chd7 morphant and mutant zebrafish larvae demonstrate reduced vagal and enteric innervation Dense foregut innervation by projections of the vagus nerve arising from the nodose ganglion was observed in control morphants (Fig. 4A) , as well as wild-type T€ ubingen larvae (Fig. 4E) . However, in chd7 morphant (Fig. 4C) , and heterozygote chd7 mutant zebrafish (chd7 +/À ) or homozygote chd7 mutant zebrafish (chd7 À/À ) larvae (Fig. 4G) , innervation of the anterior GI tract was greatly reduced. In the hindgut region, dense innervation and neuronal somata were preserved in both control morphants (Fig. 4B ) and wild-type larvae (Fig. 4F) . In chd7 morphant (Fig. 4D ) and chd7 +/À or chd7 À/À larvae ( Fig. 4H ), hindgut innervation appeared reduced but was more persistent than the foregut vagal projections.
chd7 morphant zebrafish larvae exhibit decreased intestinal motility
To investigate any changes in GI motility in the 5 dpf chd7 morphant zebrafish, we used a microgavage . Larvae lacking function of one or both copies of chd7 have pericardial edema (asterisk) and abnormal hearts with a large proportion of larvae having cardiomegaly, lack of swim bladder inflation, and alterations in melanocyte patterning (arrow). This phenotype was also seen in the morphant, morpholino-injected zebrafish larvae. Bar = 250 lm.
technique that allowed for the insertion of precise quantities of fluorescent microspheres directly into the GI tract of the larvae. Images of control and chd7 morphant larvae taken immediately after gavage (0 h), as well as 6 and 24 h postgavage, allowed us to quantify the progression of beads through the GI tracts of these fish over a 24-h observation period (Fig. 5 ). chd7 morphant larvae showed delayed passage of beads through the GI tract. When considering each bead location (1-4 and E) as an ordinal factor, no significant difference was observed between chd7 morphants and controls at either 6 or 24 h postgavage ( Fig. 6B,C ; P > 0.05). However, when comparing empty (E) versus nonempty GI tracts at 24 h postgavage (the only time point where any empty GI tracts were observed in either group), the proportion of 'empty' for control larvae was significantly higher than for chd7 morphants (Fig. 6C , n = 14-17). Specifically, the odds of having an empty GI tract at 24 h for a chd7 morphant was 0.13 (95% CI = 0.0241-0.705; P = 0.0122). Only 28% of chd7 morphant larvae displayed empty GI tracts, compared to 76% of control morphant larvae at the 24 h time point. Proportions of empty versus nonempty intestines at 24 h postgavage are similar in control and chd7 +/À heterozygous mutant larvae (~67%), however only 33% of chd7 À/À homozygous mutant larvae had empty GI tracts at this time point ( Fig. 7 ), which represents a significant reduction in motility (OR = 0.24; 95% CI = 0.058-0.98; P = 0.047).
Atropine inhibits GI motility in both chd7 and control morphants
The reduced vagal innervation of the GI tract in chd7 morphant larvae could result in reduced parasympathetic tone in this organ. To examine this, chd7 morphant larvae were incubated in 100 mgÁmL À1 atropine [17] for 24 h postgavage. Untreated (vehicle control, 2% DMSO) control and chd7 morphant larvae were consistent with earlier experiments. The incidence of empty GI tracts in the control group was significantly lower in the atropine-treated groups versus untreated groups (P = 0.038), with none of the atropine-treated fish having empty GI tracts at this time point (Fig. 8A ). Most fish retained beads in the midgut (region 3), with 83% of control fish having beads in this region after 24 h of atropine treatment (Fig. 8A ). There were also no fish with empty GI tracts after 24 h from the chd7 morphant group treated with atropine; however, this was not significantly different compared to the nontreated chd7 group ( Fig. 8B ; P = 0.24). The lack of a more profound difference as observed in the control group is likely as a result of the inherent impairment in motility in this group at baseline, as shown in our previous results (Fig. 6 ).
Prokinetic agents do not significantly improve GI motility
With evidence of reduced GI motility in chd7 morphant larvae, we next explored whether this functional impairment could be ameliorated with pharmacologic intervention using the common prokinetic agents, domperidone, and erythromycin. Domperidone had no significant effect on intestinal emptying in either standard ( Fig Although not significant, the emptying of domperidone-treated control morphants trended toward slowing rather than improving; 34% of the population emptied their GI tract after 24-h exposure to domperidone compared to 64% of the untreated control fish (Fig. 9A) . Also, while treatment with erythromycin appeared to accelerate the passage of beads at the 6-h time point in standard control morphants, by 24 h the control fish had similar percentages of empty GI tracts to those that were untreated ( Fig. 9A , C; OR = 0.97, P = 1). After 24 h of exposure to each of these drugs, 51% and 52% of chd7 morphants treated with domperidone and erythromycin, respectively, emptied their GI tracts, compared with only 35% of untreated chd7 morphants (Fig. 9B) ; however, this was not found to be a statistically significant improvement (OR = 1.922; P = 0.37 and OR = 1.965; P = 0.35, respectively).
Discussion
Using a zebrafish model of CHD7-deficient CHARGE syndrome, we show for the first time that decreased size of the GI tract, and reduced vagal innervation of this organ may contribute to the functional limitations experienced by these patients. chd7 zebrafish morphants had a reduction in the size of their GI tracts, notably in the anterior portion of the intestinal bulb, the region that normally accommodates the bolus of ingested food (Fig. 2) . Individuals with CHARGE syndrome often have feeding problems. Chewing and swallowing difficulties have been well-documented [7, 18] , but reports by individual groups suggest that in addition, individuals with CHARGE syndrome may be limited in the amount of food they can consume in one sitting. Specifically, our group has collected clinical information internationally using voluntary surveys in which parents or caregivers indicate that individuals with CHARGE syndrome exhibit a 'food pocketing' behavior, wherein they try to avoid swallowing food that they have chewed by holding it in their cheeks [19, 20] . Additionally, our own anecdotal experience is that patients with CHARGE syndrome have smaller stomachs on upper GI barium studies (K. Blake, unpublished) . If the size of the upper GI tract is limited in individuals with CHARGE syndrome as it is in chd7 morphants, this could potentially explain some of these food-avoidance behaviors. In addition to the physical limitation of the GI tract, functional limitations in our CHARGE zebrafish model may be a result of reduced vagal innervation. Microgavage of fluorescent microbeads revealed a significantly reduced ability of chd7 morphant fish to empty their GI tracts after 24 h compared to control fish (Fig. 6C) . Also, significantly fewer chd7 À/À larvae had empty GI tracts compared to controls (Fig. 7) . As in humans, peristalsis in the gut of the zebrafish larvae occurs in both anterograde and retrograde directions, working cooperatively to form a bolus of food that is then passed through the intestine, beginning at 4 dpf. These movements are sensitive to the application of the cholinergic-targeting agents, acetylcholine and atropine, indicating cholinergic (muscarinic) receptors are present and that acetylcholine is being produced endogenously at this stage [13] . Indeed, the somata of differentiated enteric neurons arising from the vagal neural crest are present within the developing intestinal wall as early as 2.25-3 dpf [13, 21, 22] . Early branching of the vagus nerve from the root of CNX (proposed nodose ganglion, located posteriorly and ventrally to the eye) of zebrafish larvae can be seen projecting to the GI tract by 3-4 dpf, with the more distal portions of the intestine being innervated first [22] . Here, we have shown that knockdown and knockout of chd7 in zebrafish results in a marked decrease and disorganization of extrinsic vagus nerve projections to the intestine, particularly in the foregut region (Fig. 4A,C ,E, G), as well as some reduction of enteric neuronal somata in the posterior sections of the GI tract (Fig. 4B,D,F,H) . Previous work employing chd7 morphant zebrafish showed a much more marked decrease in distal enteric nerve bodies; however, the functional consequences of this observation were not explored [23] . Interestingly, we saw a significant decrease in GI emptying at 24 h postgavage in control larvae treated with atropine (Fig. 8A) , but a lesser effect in chd7 morphant larvae (Fig. 8B) , consistent with intact cholinergic tone in wild-type fish that is impaired with the loss of chd7. These results may reflect the abnormal distribution of cholinergic nerve fibers throughout the length of intestine due to chd7 loss of function (Fig. 4) . Interestingly, defects in motility occur in the absence of any obvious histological differences in chd7 morphants and chd7 +/À and chd7 À/À mutant larvae (Fig. 3) . Altogether, if these results are indicative of what occurs in humans with CHARGE syndrome, reduced gut motility is likely a result of both innervation defects and physical limitations due to reduced size and not changes in intestinal smooth muscle.
We exploited our zebrafish model to investigate prokinetic agents with a hypothesis that these may be beneficial to individuals with CHARGE syndrome. Domperidone demonstrated minimal, nonsignificant benefit in chd7 morphants and had no effect on motility in control morphants (Fig. 9) . Dopamine receptors are subdivided into the stimulatory D1-class (D1 and D5), and the inhibitory D2-class (D2, D3, and D4) [24] . Domperidone functions primarily as an antagonist of peripheral D2 receptors present on postganglionic cholinergic nerve fibers in the intestine [25] , thereby increasing gastric motility [26] . Zebrafish have three distinct D2 receptor genes (drd2a, drd2b, and 
or E (empty) at 0 h (A), 6 h (B), and 24 h (C) postgavage (as depicted in figure overlay).
Odds ratio demonstrates a significant decrease in the proportion of chd7 morphant intestines that are empty at 24 h, compared to standard fish. OR = 0.13 (95% CI = 0.0241-0.705; P = 0.012). n = 17 (control) and 14 (chd7 morphant), from three biological replicates. drd2c) which have some nonoverlapping regions of mRNA expression in the central nervous system of larvae up to 5 dpf [27] . Domperidone may only affect certain zebrafish D2 receptors at the level of the GI tract, or act on all receptors in different cell types, thus resulting in different functional outcomes, all of which remains to be explored. Erythromycin had a limited effect on motility in both control and chd7 morphant zebrafish larvae (Fig. 9) . Erythromycin is a macrolide antibiotic that works as a motilin receptor agonist in the gut, stimulating the enteric innervation of the GI tract and causing smooth muscle contraction resulting in GI motility [28] . Erythromycin has been examined as a prokinetic agent to treat childhood gastroesophageal reflux and diabetic gastroparesis, but concerns regarding long-term antibiotic treatment, development of microbial resistance, and tachyphylaxis may limit its clinical application [29] . Our model did not show significant changes when the motilin receptor was targeted, however other compounds that work at the motilin receptor remain to be investigated as a possible treatment for intestinal motility issues in CHARGE patients. In fact, novel agonists for both the motilin receptor as well as the closely related ghrelin receptor continue to be explored for clinical use as prokinetic agents [30] . Both ghrelin and motilin have prokinetic effects on the zebrafish intestine, and genes coding for both ghrelin and motilin-like receptors are found in the zebrafish [31] . The variable response to domperidone or erythromycin in the chd7 morphant zebrafish mimics what is anecdotally described in the CHARGE community, suggesting the value of this model as a preclinical screening tool for the impact of novel motilin and ghrelin agonists on GI motility. This study has demonstrated a variety of abnormalities of the GI tract associated with the loss of chd7 in zebrafish. These findings may help provide structural and functional explanations to account for the GI difficulties beyond sucking, chewing, and swallowing, such as gastroesophageal reflux, bloating, gastroparesis, and constipation experienced by individuals with CHARGE syndrome [32] . Such ongoing difficulties represent an area of unrecognized importance in the long-term care of these individuals. The sensitivity afforded by the real-time direct visualization of bead passage in this live animal assay, revealed nuances in GI emptying between erythromycin and domperidone, highlighting the potential of this preclinical platform Fig. 9 . Prokinetic agents, domperidone and erythromycin, stimulate intestinal motility in chd7 and standard morphant larvae. Percentage of fish with fluorescent beads remaining in areas 1-4 or E (devoid of beads; empty) 24 h postgavage in both standard (A) and chd7 morphant fish (B). For standard fish (A), domperidone did not significantly reduce the proportion of fish that were able to empty their GI tracts at 24 h (OR 0.29; P = 0.07) and erythromycin did not have a significant effect (OR = 0.97, P = 1.0), when compared to a nontreated control group after 24 h (C). For chd7 morphant fish, neither domperidone nor erythromycin improved intestinal motility at 24 h (OR = 1.922 and 1.965; P = 0.37 and 0.35, respectively) (C). Standard fish n = 17, 32, 25; chd7 morphants n = 17, 33, 23; no treatment, domperidone, and erythromycin, respectively, from three biological replicates.
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The FEBS Journal 285 (2018) 2125-2140 ª 2018 Federation of European Biochemical Societies to help match a particular therapy to address GI issues in patients, as well as identify new drugs or drug combinations that may be able to relieve GI symptoms. Ultimately, the discovery of new motility agents that can be tailored to meet individual GI issues would greatly improve the quality of life of individuals with CHARGE syndrome.
Materials and methods

Zebrafish and morpholino injections
Adult zebrafish of breeding age (3 months-2 years) were housed at the Dalhousie Core Zebrafish Facility in standard 14 h light: 10 h dark conditions in 10 L tanks maintained at 28°C in keeping with standard procedures [33] . All experiments were performed with the approval of the Canadian Council of Animal Care and the Dalhousie University Committee on Laboratory Animals (Protocol number .
To obtain embryos for microinjection, groups of four female and two male fish (either T€ ubingen wild-type or casper mutant [34] were placed in 2 L breeding tanks and allowed to spawn, and embryos were collected every 15 min. Embryos were injected at the one-cell stage under a stereo-microscope (Zeiss V8, Carl Zeiss AG, Oberkochen, Germany) with~1 nL of solution containing 0.5 mM zebrafish chd7-specific morpholino (or 0.5 mM nonsense morpholino, termed 'control' morpholino) containing 0.05% phenol red (for visualization of the injection into the yolk sac), prepared in deionized water using a PLI-100 picoinjector (Harvard Apparatus, Holliston, MA, USA). All morpholino sequences are presented in Table S1 . After injection, embryos were placed in an incubator maintained at 28°C in E3 embryo medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl 2 , 0.33 mM MgSO 4 ). 1-phenyl 1-thiourea to a final concentration of 0.03%, was added to the egg medium of T€ ubingen embryos that were used for immunohistochemistry analysis to prevent the production of pigment. Embryos were raised to various larval stages (3-6 dpf), embryo medium was refreshed and dead larvae were removed daily. Initial experiments used morpholinos targeting either the translational start site (translation blocked morphant) or the splicing of exon 15 and intron 15 (splice site targeted morphant) [12] . Both morphant groups produced a CHARGE-like phenotype (Fig. 1) . The phenotype of the translation blocked morphants was more consistent and pronounced than the splice-blocking morphant phenotype; therefore, the translation-blocking morpholino was used for all subsequent experiments. chd7 mutant generation using CRISPR/Cas9
The target site for mutant generation (GGGGACTGT GGCTACCCTCAagg) was chosen inside exon 2 of chd7.
The corresponding single guide RNA (sgRNA , Table S1 ) was generated by performing an overlap-extension PCR as described previously [35] with T7_chd7_gRNA_sense and Rev-sgRNA-scaffold oligos (Table S1 ) using Taq DNA polymerase (G009; Applied Biological Materials Inc., Richmond, BC, Canada) and then using the resulting PCR product for in vitro transcription using MEGAshortscript T7 kit (AM1354; Thermo Fisher Scientific Inc., Waltham, MA, USA). The sgRNA was purified according to the kit instructions.
Cas9 mRNA was made from pT3TS-nCas9n plasmid [36] after its linearization with XbaI using mMessage mMachine T3 kit (AM1348; Thermo Fisher Scientific Inc.) and purified with LiCl precipitation according to the kit instructions. Cas9 mRNA and chd7 sgRNA were mixed at 400 and 200 ngÁlL À1 concentrations, respectively, and injected into 1-cell zebrafish embryos using a PLI-100 pico-injector (Harvard Apparatus). Genotyping was performed initially using T7 Endonuclease I (M0302S; New England Biolabs Inc., Ipswich, MA, USA) digestion according to the manufacturer's protocol and in subsequent genotyping we used a heteroduplex mobility assay (HMA) similar to that previously described [37] . For both assays, we used chd7 forward and reverse primers producing a 369 bp amplicon (Table S1 ) and performed PCR using Taq polymerase (10342020; Invitrogen, Waltham, MA, USA).
Nile red feeding and image analysis
In order to obtain a two-dimensional analysis of intestinal area in chd7 versus control morphants, approximately twenty 5 dpf larvae from each group were placed in 6 mL of egg medium containing 10 lgÁL À1 Nile Red (N3013;
Sigma Aldrich, Oakville, ON, Canada) in separate wells of a six well plate. Larvae were incubated overnight in the Nile Red solution in the 28°C incubator, allowing them to ingest the dye. Larvae were then rinsed three times quickly in normal E3 egg medium, then lightly anesthetized in Tricaine (0.2 mgÁmL
À1
) and imaged. Nile red was visualized and imaged using an LED light source (14 mRFP, 530 nm) on a Zeiss Discovery v20 stereoscope (Carl Zeiss AG). Images confirmed the presence of Nile Red in the intestines after this 24-h period (Fig. 2A) . The fluorescent area of the intestine was outlined using the Freehand Selection and Measurement tools of IMAGEJ (National Institutes of Health, Bethesda, MD, USA). The average selected area values are presented in Fig. 2B .
Sectioning and H & E staining
Larvae were fixed for up to 2 days at 4°C in 4% paraformaldehyde (PFA; RT-15710; Electron Microscopy Sciences, Hatfield, PA, USA) in a PBS (composition in mM: 50 Na 2 HPO 4 , 140 NaCl), pH 7.2. Fixed larvae were then embedded in small pellets of 2% low melting point agarose (A9414; Sigma Aldrich) in the appropriate orientation for sectioning along the sagittal plane. Embedded larvae were fixed in 10% neutral buffered formalin for up to 3 days. Pellets were then paraffin-embedded using the Leica EG1150 modular tissue embedding center and sectioned (5 lm) using a Leica RM2255 automated microtome (Leica Biosystems, Wetzlar, Germany). Sections were stained with H&E using a Tissue-Tek Prisma automated slide stainer and preserved using a Tissue-Tek Glas g2 automated coverslipper (Sakura Finetek USA Inc., Torrance, CA, USA) according to standard procedures.
Immunohistochemistry
Larvae were fixed overnight at 4°C in 4% PFA as described above, before processing for immunohistochemistry in whole-mount format using general procedures described previously [38, 39] . Fixed tissues were rinsed in PBS, transferred to a PBS solution containing 2% Triton X-100 (9100; Sigma Aldrich), 1% BSA (A9576; Sigma Aldrich) and 1% normal goat serum (NGS; G9023; Sigma Aldrich) for 48 h at 4°C with gentle agitation, and then incubated with primary antibodies (see below for descriptions). These were diluted in a solution containing 0.25% Triton X-100, 1% BSA and 1% NGS in PBS (designated PBS-T). Tissues were incubated for 3-5 days with agitation at 4°C, rinsed in PBS-T, then transferred to a solution of PBS-T containing the appropriate secondary antibody conjugated to AlexaFluor 488 (A-21202; Invitrogen) or 555 fluorophores (A-21422; Invitrogen). Incubation time with secondary antibody was 3-5 days with agitation at 4°C. Final washes were done in PBS before specimens were placed in Scale CUBIC-1 clearing solution [40] overnight at room temperature with gentle agitation.
To determine general innervation, antibodies against acetylated tubulin (AcT, axons; T6793; Sigma Aldrich) were combined with human neuronal protein C/D (Hu, neuronal somata; A-21271; Invitrogen). For all antibodies used in this study, a separate group was processed as outlined above, except that either the primary or secondary antibody was omitted. In all trials, this eliminated detection of histofluorescence.
Immunohistochemically labeled whole zebrafish larvae were epi-illuminated through a Zeiss LSM510 confocal microscope (Carl Zeiss AG) with a mercury lamp (X-Cite 120Q; Lumen Dynamics or 30 mW 488 nm argon and 1 mW 543 nm helium-neon lasers; Carl Zeiss AG) directed through a 488/543 nm dichroic mirror (HFT 488/543; Carl Zeiss AG) onto the preparation. Microgavage and prokinetic drug treatments chd7 and control morphant casper larvae, as well as chd7 mutants and wild-type T€ ubingen controls, were gavaged with green fluorescent microspheres at 5 dpf according to previously described protocol [41] . Briefly, larvae were lightly anesthetized in 0.2 mgÁmL À1 Tricaine prepared in E3 egg medium for the duration of the gavage procedure. After anesthesia, 30-40 larvae were placed on an agarose plate with molded grooves created specifically for microinjection, and covered with 3% methylcellulose to help steady the larvae during the gavage procedure. Larvae were positioned within the methylcellulose facing the direction of the gavage needle. Standard microinjection needles were trimmed, so that the needle tip had no jagged edges, and the needles were loaded with a solution containing 0.25% 2.00 lm FluoresbriteÒ YG Microspheres (Polysciences Inc., Warrington, PA, USA) and 0.05% phenol red (to visualize material entering the intestinal bulb) prepared in PBS. The needle was connected to the PLI-100 picoinjector (Harvard Apparatus), then guided gently into the mouth of the larva and~2 nL of the microbead solution was released into the bulb before the needle was carefully withdrawn. Successfully gavaged larvae from each of the chd7 and control morphant groups were maintained in anesthetic and immediately imaged using a fluorescent compound microscope (Axio Observer.Z1, Carl Zeiss AG) connected to a camera (Axio Cam HRm, Carl Zeiss AG) using Zen software (Zen 2 blue edition; Carl Zeiss AG) to acquire an initial '0 h' image for gut motility analysis. After initial imaging, fish were placed in individual wells of a six well plate containing E3 egg medium with no anesthesia and returned to the 28°C incubator. At 6 h postgavage, fish were re-imaged after anesthesia in 0.2 mgÁmL À1 Tricaine, and then replaced in fresh egg medium in the same six well plate in the incubator. A final image was taken at 24 h postgavage, after which the larvae were sacrificed humanely by an overdose of Tricaine (1 mgÁmL
À1
). All chd7 +/À and chd7 À/À larvae used in experiments were generated by heterozygous incross of chd7 +/À adult zebrafish. Resulting larvae were sorted based on obvious phenotypes demonstrated in Fig. 1 . After gavage experiments, genotypes were confirmed by extracting genomic DNA from the individual gavaged larvae and performing HMA analysis on each as described above. Sorted phenotypes corresponded with a chd7 +/À or chd7 À/À genotype~80% of the time (7/9 and 10/12 larvae in two individual gavage experiments). To quantify gut motility by the passage of fluorescent beads through the intestine over 24 h, the GI tract was divided into five regions [41] , 4 within the fish plus one to represent no beads in the intestine (empty, or E). Region 1 was the small portion of the GI tract located anterior to the swim bladder. Region 2 represented the portion of the GI tract that was parallel to the swim bladder. Region 3 was demarcated by the end of the swim bladder, up to the region just posterior to the area where the GI tract transitions to a straight tube. The fourth region ended at the cloaca (Fig. 5A) . If beads were not present in any of these regions, the fish was noted as empty (E) of beads. The percentage of fish in each group in which fluorescent beads were remaining in areas 1, 2, 3, and/or 4, or were completely void of beads (empty) were calculated at each time point. All gavage experiments were replicated a minimum of two times on 9-12 larvae per group, and results were pooled.
In order to examine the effect of prokinetic agents on the passage of beads in the intestine, solutions of domperidone and erythromycin were prepared in egg medium containing 2% DMSO. Doses of domperidone and erythromycin (30 and 37 mgÁmL À1 , respectively) were chosen based on maximum tolerated doses previously reported [17, 42] . After taking the initial 0 h image, each control or chd7 morphant larva was placed in individual wells of a six well plates containing either domperidone, erythromycin, or plain egg medium containing 2% DMSO as untreated controls. Fish were maintained in these drug solutions throughout the 24-h motility experiments and imaged at 6 and 24 h as described above. Images were analyzed for the passage of beads through the intestine as described above. Each prokinetic experiment was performed twice on groups of 6-9 larvae and results were pooled. Atropine experiments were performed in a similar manner with 100 mgÁmL À1 of atropine [17] in egg medium containing 2% DMSO placed in each well. This experiment was conducted once on groups of 10-11 larvae.
Statistical analysis
Since the primary outcome of the analyses was binary [empty (E) GI tracts versus nonempty at 24 h postgavage], and the experiments consisted of relatively small sample sizes, chd7 morphant gavage data were analyzed using statistical tests suitable for binary outcomes and small sample sizes [43] . Two-sided Fisher's exact tests were used to test the hypothesis of a null association between the corresponding condition (e.g., morphant or drug treatment) and having an empty (E) GI tract. In this test, the probability of obtaining the observed results if the null hypothesis is true is directly calculated using all possible 2 9 2 tables that could have been observed for the same row and column totals as the observed data. The P-value is defined as the sum of all probabilities equal to or less than that of the observed data. To measure the strength of this relationship, the odds of having an empty (E) GI tract at 24 h postgavage were estimated for chd7 relative to control morphant, or drug treated relative to untreated (odds ratio) using conditional maximum likelihood estimation [43] . Exact 95% confidence intervals for the odds ratio were constructed [44] . For the atropine experiments, there were no fish in either the control or chd7 morphant group that emptied their guts within 24 h postgavage, and so only results from the Fisher's exact tests are reported.
Estimates of the odds of having an empty (E) GI tract for atropine-treated fish relative to untreated fish and the lower limits of the 95% confidence intervals are zero and therefore undefined on the log scale. Statistical analyses were performed in R/R Studio (versions 3.3.2 and 1.0.136) [45, 46] and GRAPHPAD PRISM 7 (GraphPad Software Inc., San Diego, CA, USA). Significance for all tests was declared at P < 0.05.
